Patents Assigned to ICOS
  • Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
    Patent number: 6521619
    Abstract: The present invention relates to novel cyclopropane-containing diaryl sulfide compounds that are useful for treating inflammatory and immune diseases, to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.
    Type: Grant
    Filed: June 25, 2001
    Date of Patent: February 18, 2003
    Assignees: Icos Corporation, Abbott Laboratories
    Inventors: James T. Link, Bryan K. Sorensen
  • Inhibitors of human phosphatidylinositol 3-kinase delta
    Patent number: 6518277
    Abstract: Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K&dgr;) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3K&dgr; plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3K&dgr;, while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3K&dgr; activity, including compounds that selectively inhibit PI3K&dgr; activity. Methods of using PI3K&dgr; inhibitory compounds to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3K&dgr; inhibitory compounds to inhibit PI3K&dgr;-mediated processes in vitro and in vivo.
    Type: Grant
    Filed: April 24, 2001
    Date of Patent: February 11, 2003
    Assignee: ICOS Corporation
    Inventors: Chanchal Sadhu, Ken Dick, Jennifer Treiberg, C. Gregory Sowell, Edward A. Kesicki, Amy Oliver
  • ATR-2 cell cycle checkpoint
    Publication number: 20030023055
    Abstract: Polynucleotides encoding novel Atr-2 cell cycle checkpoint polypeptides are disclosed, along with expression constructs comprising the polynucleotides, host cells transformed with the expression constructs, methods to make the Atr-2 polypeptides using the host cells, Atr-2 polypeptides, and binding partners of the Atr-2 polypeptides.
    Type: Application
    Filed: September 21, 2001
    Publication date: January 30, 2003
    Applicant: ICOS Corporation
    Inventors: Kate Loughney, Kathleen S. Keegan
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Publication number: 20030013754
    Abstract: Pyrrole compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Application
    Filed: January 22, 2002
    Publication date: January 16, 2003
    Applicant: ICOS Corporation
    Inventors: Timothy J. Martins, Kerry W. Fowler, Amy Oliver, Carmen C. Hertel
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Patent number: 6500856
    Abstract: Novel compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: December 14, 2001
    Date of Patent: December 31, 2002
    Assignee: Icos Corporation
    Inventors: Kerry W. Fowler, Amy Oliver, Joshua Odingo
  • Novel CREBa isoform
    Publication number: 20020197712
    Abstract: The present invention relates generally to a novel CREBa polypeptide isoform, polynucleotides encoding the polypeptide, expression constructs comprising the polynucleotides, host cell transformed or transfected with the polynucleotides, methods for producing the polypeptide, and methods to identify inhibitors of binding between the CREBa and other polypeptides or polynucleotides.
    Type: Application
    Filed: June 19, 2001
    Publication date: December 26, 2002
    Applicant: ICOS Corporation
    Inventor: Kathleen S. Keegan
  • Methods of identifying agents that modulate the binding between MDC and an MDC receptor
    Patent number: 6498015
    Abstract: The present invention provides purified and isolated polynucleotide sequences encoding a novel human macrophage-derived C-C chemokine designated Macrophage Derived Chemokine (MDC), and polypeptide analogs thereof. Also provided are materials and methods for the recombinant production of the chemokine, and purified and isolated chemokine protein, and polypeptide analogs thereof. Also provided are antibodies reactive with the chemokine and methods of making and using all of the foregoing.
    Type: Grant
    Filed: September 26, 1997
    Date of Patent: December 24, 2002
    Assignee: ICOS Corporation
    Inventors: Ronald Godiska, Patrick W. Gray, Carol J. Raport
  • Thiazole compounds as cyclic AMP-specific phosphodiesterase inhibitors and method of using the same
    Patent number: 6486186
    Abstract: Novel compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: September 18, 2001
    Date of Patent: November 26, 2002
    Assignee: ICOS Corporation
    Inventors: Kerry W. Fowler, Joshua Odingo
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Publication number: 20020169196
    Abstract: Novel compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Application
    Filed: February 15, 2002
    Publication date: November 14, 2002
    Applicant: ICOS Corporation
    Inventors: Timothy J. Martins, Kerry W. Fowler, Joshua Odingo, Laurence E. Burgess, Stephen T. Schlachter
  • Lectomedin materials and methods
    Patent number: 6479256
    Abstract: Disclosed are novel seven transmembrane receptor polypeptides having characteristic extracellular structure including lectin-binding, olfactomedin-like and mucin-like domains.
    Type: Grant
    Filed: March 4, 1999
    Date of Patent: November 12, 2002
    Assignee: ICOS Corporation
    Inventor: Joel S. Hayflick
  • Transmission quality reporting
    Patent number: 6477355
    Abstract: In a satellite mobile telecommunication system, TDMF traffic is transmitted from a SAN 1 via a satellite 3 to a mobile user terminal UT1, over a duplex link 1, 2. The SAN 1 instructs the satellite 3a to transmit signals over link 1 to UT 1 at a power level dependent upon the quality of signal received by UT 1, so as to adaptively control the power to an efficient level. Similarly, the power level of signals transmitted by UT 1 to the satellite is controlled depending on the error rate. The power level required is computed as a function of the average of easured areas determined during a given measurement period together with a margin which is computed as an adaptive function of a deviation of the errors bout the average value.
    Type: Grant
    Filed: March 25, 1999
    Date of Patent: November 5, 2002
    Assignee: ICO Services LTD
    Inventors: Mark Grayson, Dennis Roy Mullins
  • Carboline derivatives as cGMP phosphodiesterase inhibitors
    Patent number: 6462047
    Abstract: Compounds of general structural formula (I) wherein A represents a 5- or 6-membered heteroaryl group containing at least one heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur, and use of the compounds, and salts and solvates thereof, as therapeutic agents, are disclosed.
    Type: Grant
    Filed: May 16, 2001
    Date of Patent: October 8, 2002
    Assignee: ICOS Corporation
    Inventors: Agnes Bombrun, Françoise Gellibert
  • Materials and methods for modulating differentiation
    Publication number: 20020142976
    Abstract: This invention generally relates to materials and methods for modulating the differentiation of cells. Specifically provided are methods to promote or inhibit cell differentiation and methods to identify compounds that promote cellular differentiation.
    Type: Application
    Filed: March 27, 2001
    Publication date: October 3, 2002
    Applicant: ICOS Corporation
    Inventors: Merl F. Hoekstra, Mathew J. Thayer
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Patent number: 6458787
    Abstract: Novel pyrrolidine compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: May 2, 2001
    Date of Patent: October 1, 2002
    Assignee: ICOS Corporation
    Inventors: Timothy J. Martins, Kerry W. Fowler, Joshua Odingo, Edward A. Kesicki, Amy Oliver, Laurence E. Burgess, John J. Gaudino, Zachary S. Jones, Bradley J. Newhouse, Stephen T. Schlacter
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Patent number: 6455562
    Abstract: Novel compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: September 14, 2001
    Date of Patent: September 24, 2002
    Assignee: Icos Corporation
    Inventors: Kerry W. Fowler, Joshua Odingo
  • Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
    Patent number: 6451807
    Abstract: The present invention relates to highly selective phosphodiesterase (PDE) enzyme inhibitors and to their use in methods of treating sexual dysfunction in individuals suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction.
    Type: Grant
    Filed: April 26, 2000
    Date of Patent: September 17, 2002
    Assignee: Lilly Icos, LLC.
    Inventors: Jeffrey T. Emmick, Kenneth M. Ferguson, William E. Pullman, John S. Whitaker
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Patent number: 6444671
    Abstract: Novel compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: November 15, 2001
    Date of Patent: September 3, 2002
    Assignee: ICOS Corporation
    Inventor: John J. Gaudino
  • Tetracyclic derivatives, process of preparation and use
    Publication number: 20020119976
    Abstract: A compound of formula (I) 1
    Type: Application
    Filed: February 5, 2002
    Publication date: August 29, 2002
    Applicant: ICOS Corporation
    Inventor: Alain Claude-Marie Daugan
  • Methods of inhibiting locomotor damage following spinal cord injury with &agr; D-specific antibodies
    Patent number: 6432404
    Abstract: Methods to treat spinal cord injury using &agr;d monoclonal antibodies are disclosed.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: August 13, 2002
    Assignee: ICOS Corporation
    Inventors: W. Michael Gallatin, Monica Van der Vieren
  • Monocyte chemotactic protein-5 materials and methods
    Publication number: 20020102642
    Abstract: The present invention provides purified and isolated polynucleotide sequences encoding a novel human macrophage-derived C—C chemokine designated MCP-5. Also provided are purified and isolated chemokine protein, fragments and polypeptide analogs thereof, antibodies thereto, and materials and methods for the recombinant production thereof. These products are useful in therapeutic, diagnostic and medical imaging applications.
    Type: Application
    Filed: June 1, 2001
    Publication date: August 1, 2002
    Applicant: ICOS Corporation
    Inventors: Ronald Godiska, Patrick W. Gray